Adela-Corina Nechifor-Boilă

Dr. Adela-Corina Nechifor-Boilă

Histology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Romania, Târgu-Mureş, Mureş, Romania
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2021 in Life
Verified
Journal Article
Open access
PDF file
INIoan Alin Nechifor-Boila
Ioan Alin Nechifor-Boila
ALAndrada Loghin
Andrada Loghin
ANAdela-Corina Nechifor-Boilă
Adela-Corina Nechifor-Boilă
MDMyriam Decaussin-Petrucci
Myriam Decaussin-Petrucci
SVSeptimiu Voidăzan
Septimiu Voidăzan
ABAngela Borda
Angela Borda
In the present study, we analyzed Programmed Death Ligand-1 (PD-L1) expression in radical cystectomy (RC) specimens from patients with muscle-invasive urothelial carcinoma (UC), in order to assess any correlations with specific clinicopathological features and its potential prognostic value. A multi-institutional study was performed within the departments of urology and pathology at the Mureș County Hospital, Romania, and Centre Hospitalier Lyon Sud, France. Sixty-nine patients with MIBC were included, for whom tumor histology (conventional versus histological variant/differentiation), tumor extension (T), lymph node involvement (N), and distant metastases (M) were recorded. PD-L1 immunostaining was performed using the 22C3 clone and was interpreted using the combined positive score (CPS) as recommended (Dako Agilent, Santa Clara, CA, USA). Positive PD-L1 immunostaining was more prevalent among UCs with squamous differentiation compared to conventional UCs and trended towards an improved OS (p = 0.366). We found the T stage to be a risk factor for poor survival in PD-L1-positive patients (HR 2.9, p = 0.021), along with the N stage in PD-L1-negative patients (HR 1.98, p = 0.007). No other clinicopathological factor was found to be significantly associated with PD-L1 positivity. Thus, we confirm the need for PD-L1 immunostaining prior to initiating immune checkpoint inhibitor therapy for a more accurate assessment of the patients’ chances of responding to treatment.

11 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ANAdela-Corina Nechifor-Boilă
Adela-Corina Nechifor-Boilă
AZAncuţa Zahan
Ancuţa Zahan
CBClaudia Bănescu
Claudia Bănescu
VMValeriu Moldovan
Valeriu Moldovan
DPDoina Piciu
Doina Piciu
ABAngela Borda
Angela Borda
We aimed to evaluate the prognostic value of BRAFV600E mutation in a series of 127 papillary thyroid carcinoma (PTC) cases as a single factor, and in synergic interaction with other standard risk factors. BRAFV600E mutation was assessed by real-time PCR. Event-free survival (EFS) was calculated between the date of the first evaluation and the date of occurrence of an adverse event or the date of the last known status. The prevalence of BRAFV600E mutation was 57.2%. The Kaplan–Meier analysis showed a significant reduction of EFS among cases harboring BRAFV600E mutation compared to non-mutated cases (p = 0.010). In addition, BRAFV600E mutation was found to better predict adverse outcomes when associated with the following risk factors: age ≥ 55 years old (p < 0.001), male gender (p < 0.001), conventional (p = 0.005) and tall cell (p = 0.014) histology, tumor size > 40 mm (p = 0.001), extrathyroidal extension (p = 0.001), multifocality (p = 0.001) and lymph node metastasis (p < 0.001). In univariate analysis, a 3.74-fold increased risk for a reduced EFS (p = 0.018) was found for BRAFV600E-mutated cases, but no increased risk was further confirmed by multivariate analysis. Our results highlight that BRAFV600E mutation cannot be used alone as an independent predictive factor in PTC patients, but is prognostically valuable if integrated in the context of other clinicopathological risk factors.


28 February 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Andrada-Claudia TătarAndrada-Claudia Tătar
Andrada-Claudia Tătar
ALAndrada Loghin
Andrada Loghin
ANAdela-Corina Nechifor-Boilă
Adela-Corina Nechifor-Boilă
ARAndrada Raicea
Andrada Raicea
MPMaria-Cătălina Popelea
Maria-Cătălina Popelea
ABAngela Borda
Angela Borda
Background/Objectives: UBC demonstrates a relatively low prevalence in patients under 50 years old. Our study aimed to compare the pathological characteristics of UBC in young and elderly patients and to assess the age-related variations in these characteristics. Methods: This retrospective study from January 2018 to December 2022 encompassed 762 patients with an initial diagnosis of UBC. To evaluate the pathological characteristics of UBC in young patients, compared to elderly patients, we divided our cohort using a cut-off age of 50 years. Additionally, to evaluate the age-dependent variations in these characteristics, we further stratified our patients into three age groups (≤50, 51–70, and >70 years old). Results: Of the 762 patients included in our study, 37 (4.86%) were young (≤50 years old), with a median age of 44 and a M:F ratio of 3.11:1. Conventional UC was the most common histology (86.5%). Regarding tumour grade, we noticed a higher prevalence of PUNLMP (10.8% versus 2.3%) and LGPUC (45.9% versus 37.1%) and a lower prevalence of HGPUC (43.2% versus 60%) and CIS (0% versus 0.6%) in young patients (p = 0.008). In this group, the pTa stage revealed a higher prevalence (64.9% versus 46.8%), while pT1 and pT2 showed a lower prevalence (32.1% versus 18.9% and 20.6% versus 16.2%) (p = 0.179). All results remained consistent when the cohort was stratified into three age groups, showing age-related variations (p = 0.001 and p = 0.089, respectively). Conclusions: In young patients, UBC tends to be of a lower grade and stage compared to elderly patients, and these characteristics demonstrate a gradual age-related stratification.

5 March 2025 in Foods
Verified
Journal Article
Open access
PDF file
CFCristina Filip
Cristina Filip
Ruxandra StefanescuRuxandra Stefanescu
Ruxandra Stefanescu
BŐBianca-Eugenia Ősz
Bianca-Eugenia Ősz
A(Amalia Pușcaș (Miklos)
Amalia Pușcaș (Miklos)
Corneliu TanaseCorneliu Tanase
Corneliu Tanase
AVAmelia Tero Vescan
Amelia Tero Vescan
The growing consumption of processed foods, including meat-based and plant-based burgers (PBM), raises concerns about their long-term health effects. While PBM burgers are marketed as healthier alternatives, their biochemical and histological impacts remain unclear. This study investigates the effects of chronic meat-based and PBM burger consumption on metabolic and organ health, considering sex differences. Thirty-six Wistar rats (18 males and 18 females) were divided into three groups: control (standard chow), meat burger-fed, and PBM burger-fed. Improved chow was prepared using lyophilized burger powder. Over eight weeks, food intake, weight gain, and food efficiency ratio (FER) were monitored. Serum biochemical markers, including AST, ALT, urea, creatinine, lipid profile (TG, CHOL, HDL, LDL), and leptin, were analyzed, alongside histopathological evaluation of the liver, kidneys, and heart. PBM-fed rats exhibited significantly higher FER than the meat group (p < 0.05). AST and ALT levels were slightly elevated in meat-fed rats, while PBM-fed males had increased urea levels. Triglyceride levels were significantly higher in the meat group, but cholesterol levels did not differ significantly. Serum leptin was elevated in both experimental groups, suggesting leptin resistance. Histological findings showed mild hepatic inflammation and microvacuolar changes, with minor cardiac fibrosis. These findings highlight the need for further research on PBM’s long-term health effects.

29 August 2025 in Medicina
Verified
Journal Article
Open access
PDF file
Georgian-Nicolae RaduGeorgian-Nicolae Radu
Georgian-Nicolae Radu
LCLaura Chinezu
Laura Chinezu
RCRamona Teodora Cătană
Ramona Teodora Cătană
PCPetre Carabasa
Petre Carabasa
ANAdela-Corina Nechifor-Boilă
Adela-Corina Nechifor-Boilă
Background and Objectives: Lung cancer (LC) remains a significant global health issue with poor prognosis. The COVID-19 pandemic has caused delays in cancer patient management worldwide. However, its impact on the incidence of LCs in Romania has not yet been discussed. We aimed to evaluate the impact of lockdown restrictions during the COVID-19 pandemic on new LC diagnoses in a Romanian cohort and the potential associations between demographic characteristics and histological features. Materials and Methods: This retrospective study analyzed 750 patients with lung tumors diagnosed in the Pathology Department, Mureș County Clinical Hospital, Romania, between 2018 and 2022. The target population was divided in two cohorts: pre-COVID-19 (1 January 2018–15 March 2020) and COVID-19 (16 March 2020–31 December 2022). Results: The temporal trend of LC diagnosis followed a descending pattern over the study period, with a significant 72% reduction (p < 0.001) in the first year of the COVID-19 pandemic (2020 vs. 2019). In terms of histology, several subtypes displayed a notable reduction in the COVID-19 cohort compared to the pre-pandemic period: squamous carcinoma (SQC) (p < 0.001), adenocarcinoma (ADK) (p < 0.001), and lung metastases (p = 0.0008). On the other hand, cases of non-small-cell lung carcinomas not otherwise specified (NSCLCs NOS) experienced a significant increase in the pandemic years (p = 0.0406). SQC was the most frequent subtype of LC and was significantly more frequent in men (p < 0.001, RR = 1.3004, 95% CI [1.1786–1.4347]). Furthermore, a notable shift in the male-to-female ratio was observed between the two cohorts, caused by a larger decrease in the incidence of LC among men compared to females in the COVID-19 period (p = 0.0002; pre-COVID-19 M/F = 4/1 versus COVID-19 M/F = 2/1). Conclusions: COVID-19-related restrictions led to a significant drop in new LC diagnoses during the first year of the pandemic, which was followed by a slight upward trend in the subsequent years. Additionally, the sharp decline in the number of cases among men narrowed the gender gap in LC patients.